Company Overview - Kyowa Kirin Co., Ltd. is a Japan-based Global Specialty Pharmaceutical Company with over 70 years of experience in drug discovery and biotechnology innovation [7] - The company focuses on developing novel medicines and treatments for high unmet medical needs, including bone & mineral diseases, hematological diseases, and rare diseases [7] Product Development - Rocatinlimab is an investigational anti-OX40 human monoclonal antibody targeting moderate to severe atopic dermatitis, with the potential to be the first T-cell rebalancing therapy [5][6] - The Phase 3 ROCKET IGNITE trial results for rocatinlimab will be presented at the EADV 2025 Annual Meeting in Paris from September 17-20, 2025 [1][3] - The ROCKET program consists of eight studies aimed at establishing the safety and efficacy profile of rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis [3] Market Context - Atopic dermatitis affects 15-20% of children and up to 10% of adults, characterized by chronic symptoms and unpredictable flare-ups [4] - The disease is driven by T-cell imbalance, which is a root cause of its inflammatory nature [2][4] Collaboration - Kyowa Kirin has a collaboration agreement with Amgen to jointly develop and commercialize rocatinlimab, with Amgen leading development globally except in Japan [8]